North America Endocrine Disruption Screening Market : Table of Contents

1. Introduction

1.1 Report Guidance

1.2 Market Segmentation

2. Executive Summary

2.1 Key Market Insights

2.2 Market Attractiveness

3. Research Methodology

3.1 Secondary Research

3.2 Primary Research

3.2.1 Data Triangulation and Validation

4. North America Endocrine Disruption Screening Market Landscape

4.1 Overview

4.3 Ecosystem Analysis

4.3.1 List of Vendors in the Value Chain

5. North America Endocrine Disruption Screening Market – Key Market Dynamics

5.1 Market Drivers

5.2 Market Restraints

5.3 Market Opportunities

5.4 Future Trends

5.5 Impact of Drivers and Restraints

6. North America Endocrine Disruption Screening Market Regional Analysis

6.2 North America Endocrine Disruption Screening Market Revenue 2019-2028 (US$ Million)

6.3 North America Endocrine Disruption Screening Market Forecast Analysis

7. North America Endocrine Disruption Screening Market Analysis – by Assay Type

7.1 In-Vitro

7.1.1 Overview
7.1.2 In-Vitro: North America Endocrine Disruption Screening Market – Revenue and Forecast, 2019-2028 (US$ Million)

7.2 In-Vivo

7.2.1 Overview
7.2.2 In-Vivo: North America Endocrine Disruption Screening Market – Revenue and Forecast, 2019-2028 (US$ Million)

8. North America Endocrine Disruption Screening Market Analysis – by Application

8.1 Natural materials and Synthetic materials

8.1.1 Overview
8.1.2 Natural materials and Synthetic materials: North America Endocrine Disruption Screening Market – Revenue and Forecast, 2019-2028 (US$ Million)

9. North America Endocrine Disruption Screening Market Analysis – by Sources of waste

9.1 Incineration and landfill

9.1.1 Overview
9.1.2 Incineration and landfill: North America Endocrine Disruption Screening Market – Revenue and Forecast, 2019-2028 (US$ Million)

9.2 Agricultural runoff

9.2.1 Overview
9.2.2 Agricultural runoff: North America Endocrine Disruption Screening Market – Revenue and Forecast, 2019-2028 (US$ Million)

9.3 Industrial and municipal effluents

9.3.1 Overview
9.3.2 Industrial and municipal effluents: North America Endocrine Disruption Screening Market – Revenue and Forecast, 2019-2028 (US$ Million)

9.4 Pulp mill effluents

9.4.1 Overview
9.4.2 Pulp mill effluents: North America Endocrine Disruption Screening Market – Revenue and Forecast, 2019-2028 (US$ Million)

9.5 Consumer products

9.5.1 Overview
9.5.2 Consumer products: North America Endocrine Disruption Screening Market – Revenue and Forecast, 2019-2028 (US$ Million)

10. North America Endocrine Disruption Screening Market Analysis – by Method

10.1 Estrogen Receptor Transactivation

10.1.1 Overview
10.1.2 Estrogen Receptor Transactivation: North America Endocrine Disruption Screening Market – Revenue and Forecast, 2019-2028 (US$ Million)

10.2 Androgen Receptor Transactivation

10.2.1 Overview
10.2.2 Androgen Receptor Transactivation: North America Endocrine Disruption Screening Market – Revenue and Forecast, 2019-2028 (US$ Million)

10.3 Androgen Receptor Modulation

10.3.1 Overview
10.3.2 Androgen Receptor Modulation: North America Endocrine Disruption Screening Market – Revenue and Forecast, 2019-2028 (US$ Million)

10.4 Estrogen Receptor-alpha Binding

10.4.1 Overview
10.4.2 Estrogen Receptor-alpha Binding: North America Endocrine Disruption Screening Market – Revenue and Forecast, 2019-2028 (US$ Million)

10.5 Estrogen Receptor-beta Binding

10.5.1 Overview
10.5.2 Estrogen Receptor-beta Binding: North America Endocrine Disruption Screening Market – Revenue and Forecast, 2019-2028 (US$ Million)

10.6 Androgen Receptor Binding

10.6.1 Overview
10.6.2 Androgen Receptor Binding: North America Endocrine Disruption Screening Market – Revenue and Forecast, 2019-2028 (US$ Million)

10.7 Steroidogenesis

10.7.1 Overview
10.7.2 Steroidogenesis: North America Endocrine Disruption Screening Market – Revenue and Forecast, 2019-2028 (US$ Million)

10.8 Aromatase Assay

10.8.1 Overview
10.8.2 Aromatase Assay: North America Endocrine Disruption Screening Market – Revenue and Forecast, 2019-2028 (US$ Million)

11. North America Endocrine Disruption Screening Market – North America Analysis

11.1 Overview

11.2 North America

11.2.1 North America Endocrine Disruption Screening Market Breakdown, by Key Country, 2022 and 2028 (%)
11.2.1.1 North America Endocrine Disruption Screening Market – Revenue and Forecast Analysis – by Country
11.2.1.1 US: North America Endocrine Disruption Screening Market – Revenue and Forecast to 2028 (US$ Million)

11.2.1.1.1 US: North America Endocrine Disruption Screening Market Breakdown, by Assay Type
11.2.1.1.2 US: North America Endocrine Disruption Screening Market Breakdown, by Application
11.2.1.1.3 US: North America Endocrine Disruption Screening Market Breakdown, by Sources of waste
11.2.1.1.4 US: North America Endocrine Disruption Screening Market Breakdown, by Method

11.2.1.2 Canada: North America Endocrine Disruption Screening Market – Revenue and Forecast to 2028 (US$ Million)

11.2.1.2.1 Canada: North America Endocrine Disruption Screening Market Breakdown, by Assay Type
11.2.1.2.2 Canada: North America Endocrine Disruption Screening Market Breakdown, by Application
11.2.1.2.3 Canada: North America Endocrine Disruption Screening Market Breakdown, by Sources of waste
11.2.1.2.4 Canada: North America Endocrine Disruption Screening Market Breakdown, by Method

11.2.1.3 Mexico : North America Endocrine Disruption Screening Market – Revenue and Forecast to 2028 (US$ Million)

11.2.1.3.1 Mexico : North America Endocrine Disruption Screening Market Breakdown, by Assay Type
11.2.1.3.2 Mexico : North America Endocrine Disruption Screening Market Breakdown, by Application
11.2.1.3.3 Mexico : North America Endocrine Disruption Screening Market Breakdown, by Sources of waste
11.2.1.3.4 Mexico : North America Endocrine Disruption Screening Market Breakdown, by Method

12. Competitive Landscape

12.1 Heat Map Analysis

12.2 Company Positioning and Concentration

13. Industry Landscape

13.1 Overview

13.2 Market Initiative

13.3 Partnerships and Collaborations

13.4 Other Developments

14. Company Profiles

14.1 aALPHA ANALYTICAL, Inc.

14.1.1 Key Facts
14.1.2 Business Description
14.1.3 Products and Services
14.1.4 Financial Overview
14.1.5 SWOT Analysis
14.1.6 Key Developments

14.2 Charles River Laboratories, Inc.

14.2.1 Key Facts
14.2.2 Business Description
14.2.3 Products and Services
14.2.4 Financial Overview
14.2.5 SWOT Analysis
14.2.6 Key Developments

14.3 Creative Bioarray

14.3.1 Key Facts
14.3.2 Business Description
14.3.3 Products and Services
14.3.4 Financial Overview
14.3.5 SWOT Analysis
14.3.6 Key Developments

14.4 Eurofins Scientific Ltd.

14.4.1 Key Facts
14.4.2 Business Description
14.4.3 Products and Services
14.4.4 Financial Overview
14.4.5 SWOT Analysis
14.4.6 Key Developments

14.5 JRF Global

14.5.1 Key Facts
14.5.2 Business Description
14.5.3 Products and Services
14.5.4 Financial Overview
14.5.5 SWOT Analysis
14.5.6 Key Developments

14.6 M?rieux NutriSciences

14.6.1 Key Facts
14.6.2 Business Description
14.6.3 Products and Services
14.6.4 Financial Overview
14.6.5 SWOT Analysis
14.6.6 Key Developments

14.7 SGS SA

14.7.1 Key Facts
14.7.2 Business Description
14.7.3 Products and Services
14.7.4 Financial Overview
14.7.5 SWOT Analysis
14.7.6 Key Developments

14.8 Smithers

14.8.1 Key Facts
14.8.2 Business Description
14.8.3 Products and Services
14.8.4 Financial Overview
14.8.5 SWOT Analysis
14.8.6 Key Developments

15. Appendix

15.1 About Business Market Insights

15.2 List of Abbreviations

North America Endocrine Disruption Screening Market